Renaissance Capital logo

RNAZ News

US IPO Weekly Recap: Micro-caps lead a quiet 2 IPO week

RNAZ

After a record breaking number of deals last week, the IPO market cooled off for the shortened holiday week, with just two micro-cap IPOs raising $45 million.  Preclinical RNA biotech Transcode Therapeutics (RNAZ) priced at $4 to...read more

Micro-cap oncology biotech TransCode Therapeutics prices IPO at $4

TransCode Therapeutics logo

Transcode Therapeutics, a preclinical biotech developing RNA-based targeted therapies for cancer, raised $25 million by offering 6.25 million shares at $4.00. At $4.00, TransCode Therapeutics commands a fully diluted market value of $54 million. The company...read more

Oncology biotech Transcode Therapeutics slashes valuation by 41% ahead of $25 million IPO

TransCode Therapeutics logo

Transcode Therapeutics, a preclinical biotech developing RNA-based targeted therapies for cancer, amended the terms for its upcoming IPO on Monday. The Boston, MA-based company now plans to raise $25 million by offering 6.3 million shares at $4. The company...read more

Oncology biotech Transcode Therapeutics sets terms for $25 million IPO

TransCode Therapeutics logo

Transcode Therapeutics, a preclinical biotech developing RNA-based targeted therapies for cancer, announced terms for its IPO on Wednesday. The Boston, MA-based company plans to raise $25 million by offering 2.8 million shares at a price range of $8 to $10....read more